These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 15711777)

  • 1. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
    Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance.
    Pepe J; Petrucci MT; Nofroni I; Fassino V; Diacinti D; Romagnoli E; Minisola S
    Br J Haematol; 2006 Sep; 134(5):485-90. PubMed ID: 16848794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D; Neacşu E; Marinescu M; Popa O
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
    Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
    J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
    Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
    Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A; Altavilla D; Squadrito G; Romeo A; Adamo EB; Marini R; Inferrera MA; Marini H; Bitto A; D'Anna R; Corrado F; Bartolone S; Frisina N; Squadrito F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.